- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05901051
High-dose Dual Therapy With Different Administration Frequencies
December 17, 2023 updated by: Hong Lu, MD, Shanghai Jiao Tong University School of Medicine
Randomized and Controlled Clinical Study of High-dose Dual Therapy With Different Administration Frequencies in the Treatment of Helicobacter Pylori
This study is a single center, randomized controlled clinical study.
The enrolled patients are HP positive.
They are diagnosed as HP positive by rapid urease test and/or 13C urea breath test.
According to the declaration of Helsinki, 327 patients will be included in this study.
After obtaining the written informed consent of the patients, HP culture and drug sensitivity test will be conducted on all the selected patients with the success rate, adverse reactions, compliance, antibiotic resistance of HP and its impact on HP eradication.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
According to relevant literature research, amoxicillin TID groups (including before meal group and after meal group) were given Vonorasen (Takeda China) 20mg bid and Amoxicillin 1.0 TID (Zhejiang Jinhua Kangenbei biopharmaceutical Co., Ltd.).
Amoxicillin Qid group was given Vonorasen (Takeda China) 20mg bid and Amoxicillin 0.75 Qid (Zhejiang Jinhua Kangenbei biopharmaceutical Co., Ltd.), all the drugs were purchased by the patients from the hospital.
The three groups were treated for 14 days respectively, and 13C urea breath test was performed 6 weeks after drug withdrawal.
The negative ones were judged as HP eradication.
Study Type
Interventional
Enrollment (Actual)
327
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200127
- Renji Hospital, School of Medicine, Shanghai Jiao Tong University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Ability and willingness to participate in the study and to sign and give informed consent
- Confirmed H. pylori infection
Exclusion Criteria:
- Pregnant and lactating women;
- History of gastrointestinal malignancies;
- History of previous subtotal gastrectomy;
- Serious dysfunction of heart, liver, kidney, lung and other important organs and congenital diseases; Such as grade IV cardiac insufficiency, liver failure, uremia, respiratory failure, hemophilia, Wilson disease, etc;
- History of hematological diseases
- People who are allergic to drugs;
- The guardian or patient refused to join the group;
- Alcohol and / or drug abuse (addiction or dependence) or poor compliance judged by doctors;
- No legal capacity or poor self-knowledge
- administration of antibiotics, bismuth, antisecretory drugs, or Chinese herb medicine in the preceding 8 weeks
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: dual therapy A
Vonoprazan 20mg bid ac and amoxicillin 0.75g qid pc
|
Antibiotics for H. pylori eradication
Potassium competitive acid blocker
|
Experimental: dual therapy B
Vonoprazan 20mg bid ac and amoxicillin 1g tid pc
|
Antibiotics for H. pylori eradication
Potassium competitive acid blocker
|
Experimental: dual therapy C
Vonoprazan 20mg bid ac and amoxicillin 1g tid ac
|
Antibiotics for H. pylori eradication
Potassium competitive acid blocker
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Helicobacter pylori eradication rate
Time Frame: Six weeks after completion of therapy
|
Six weeks after completion of therapy, H. pylori eradication was assessed by ¹³C-rea breath test.
Eradication was defined as negative result from urea breath test (<4‰) (4‰ as the cutoff value).
|
Six weeks after completion of therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compliance rate
Time Frame: Within 7 days after completion of therapy
|
Compliance was defined as poor when they had taken less than 80% of the total medication
|
Within 7 days after completion of therapy
|
Rate of adverse events
Time Frame: Within 7 days after completion of therapy
|
The subjects were asked to record side effects and discomfort during treatment and actual drug administration.
|
Within 7 days after completion of therapy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 30, 2021
Primary Completion (Actual)
September 10, 2023
Study Completion (Actual)
September 30, 2023
Study Registration Dates
First Submitted
February 24, 2023
First Submitted That Met QC Criteria
June 4, 2023
First Posted (Actual)
June 13, 2023
Study Record Updates
Last Update Posted (Estimated)
December 21, 2023
Last Update Submitted That Met QC Criteria
December 17, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- rjyy20210815
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Helicobacter Pylori Infection
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...RecruitingHelicobacter Pylori Infection | Helicobacter Pylori EradicationBangladesh
-
Shandong UniversityRecruitingHelicobacter Pylori Infection | Patient Education | Helicobacter Pylori EradicationChina
-
Shandong UniversityCompletedHelicobacter Pylori Infection Helicobacter Pylori Eradication Patient EducationChina
-
Shanghai Jiao Tong University School of MedicineCompletedCure Rate of Helicobacter Pylori InfectionChina
-
Seoul National University Bundang HospitalRecruitingHelicobacter Pylori Infection | Helicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation | Helicobacter Pylori Associated Gastrointestinal Disease | Helicobacter Pylori Infection, Susceptibility toKorea, Republic of
-
The First Affiliated Hospital of Nanchang UniversityUnknownBacterial Infection Due to Helicobacter Pylori (H. Pylori) | Eradication Therapy of Helicobacter Pylori | Detection of Helicobacter PyloriChina
-
Tanta UniversityNot yet recruitingPersistent Helicobacter Pylori InfectionEgypt
-
Nanjing First Hospital, Nanjing Medical UniversityCompletedHelicobacter Pylori 23S rRNA/gyrA Gene Mutation Detection Kit (Fluorescence PCR Fusion Curve Method)Helicobacter Pylori Infection | Helicobacter Pylori gyrA Levofloxacin Resistance Mutation | Fecal Drug Resistance Gene Detection | Helicobacter Pylori Infection, Susceptibility toChina
-
Kaohsiung Veterans General Hospital.Kaohsiung Medical University Chung-Ho Memorial HospitalCompletedHelicobacter Pylori InfectionTaiwan
-
National Taiwan University HospitalCompleted
Clinical Trials on Amoxicillin
-
Universita degli Studi di GenovaNot yet recruiting
-
Saskatchewan Health Authority - Regina AreaNot yet recruiting
-
University of Alabama at BirminghamMerck Sharp & Dohme LLCCompletedPostpartum Sepsis | Postpartum Endometritis | Postpartum FeverCameroon
-
University Medical Centre LjubljanaUniversity of Ljubljana School of Medicine, SloveniaRecruiting
-
Malmö UniversityCompletedAntibiotic Prophylaxis | Infection ControlSweden
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityCompletedHelicobacter Pylori Eradication RateChina
-
Assistance Publique - Hôpitaux de ParisCompletedChronic Obstructive Lung Disease (COLD)France
-
Ranbaxy Laboratories LimitedCompletedHealthyUnited States
-
University Hospital, Clermont-FerrandUnknown
-
Klara Posfay-BarbeGertrude Von Meissner Foundation; Recherche et Développement des HUG; Société...UnknownGroup A Streptococcal PharyngitisSwitzerland